The earlier someone is diagnosed with Alzheimer’s disease the earlier treatment may begin. The ability to plan for the future and utilize resources may then be done before cognition is diminished.
Finally, a blood test is market-ready that can identify amyloid plaque, the strongest pathological hallmark of Alzheimer’s disease in the brain. C2N Diagnostics’ PrecivityAD™ is the inexpensive, easily administered, and quick diagnostic tool we’ve been long-awaiting. The test appears to be about 86% accurate in measuring concentrations of amyloid beta 42 and 40 (Aß42 and Aß40), and the presence of apolipoprotein E (ApoE) isoforms in blood.
PET scans detect the plaque, as well, however, this test is expensive and is not typically covered by insurance. With both PET scans and the new blood test, clinical presentation of symptoms also must be observed in a final diagnosis.
In addition, the PrecivityAD™ blood test promotes more appropriate treatment for patients suffering from other dementias that were previously assumed to be Alzheimer’s. This test is available in 45 states, the District of Columbia, and Puerto Rico. For more information, visit www.PrecivityAD.com or call 1-877-266-3424.